Aptar’s regulated Pharma moat, injectables growth, and 8.6/10 quality profile support long-term compounding despite temporary margin and destocking pressures.
Overview
Aptargroup is a global engineering partner supplying regulated drug-delivery devices, injectable components, beauty pumps, sprayers, and specialized closures to pharmaceutical, biotech, consumer-health, food, beverage, and prestige-beauty customers. Its strongest asset is the Pharma franchise: regulated qualification, FDA Drug Master File integration, dose accuracy, and more than 750 patent families create switching costs that protect customer relationships across product lifecycles. The company serves over 5,000 customers, with no customer above 4% of FY2025 sales, and Europe represented 49% of sales in both FY2024 and FY2025. **Pharma now contributes approximately 69% of consolidated EBITDA**, helping shift the mix toward more defensive, higher-value activities. FY2025 sales were $3.78 billion, adjusted EBITDA was $815 million, and free cash flow was $299.6 million. Q2 2026 sales rose 6% to $1.03 billion and beat consensus, while adjusted EPS of $1.42 also exceeded expectations despite margin compression to 20.7%. **The valuation is approximately 22x forward P/E**, a premium to packaging peers but supported by the moat and growth profile. Catalysts include easing $65 million naloxone destocking by Q4 2026, margin recovery, injectables, buybacks, and HFA-152a adoption.